News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Adherex Technologies Inc. (ADH) Announces Agreement for STS Phase III Data


5/14/2008 11:04:46 AM

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - May 14, 2008) - Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today a license agreement with the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL) for the exclusive use of data from a Phase III trial conducted by Dr. Charlotte Zuur and colleagues of the NKI-AVL with sodium thiosulfate (STS) to prevent hearing loss in adults with head and neck cancer, published in the Journal of Clinical Oncology in August 2007 and entitled "Ototoxicity in a Randomized Phase III Trial of Intra-Arterial Compared With Intravenous Cisplatin Chemoradiation in Patients with Locally Advanced Head and Neck Cancer". The agreement includes an exclusive license to data from a planned study intended to provide long-term follow-up on the hearing status, disease-free status and overall survival of patients from the completed Phase III trial.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES